{
  "retracted": false,
  "timestamp": 1585180800000,
  "updates": [
    {
      "timestamp": 1591771850766,
      "identifier": {
        "doi": "10.1182/blood.2020005086"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1182/blood-2017-03-771220"
  },
  "journal": "Blood",
  "publisher": "American Society of Hematology",
  "title": "Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605."
}
